Friday, July 10, 2026

pharma · No medical condition. · Generalized Myasthenia Gravis

Anaxis Pharma

Lacuna Pharma Pty is a pharma organization headquartered in Colmenar Viejo, AU. Primary therapeutic focus areas include No medical condition., Generalized Myasthenia Gravis, No therapeutic indication in the current trial

Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2017
Employees
7
Programs
642
Drugs
673
Patents
0
Clinical program

RP-L301-0119

Phase 1 · small molecule · Inherited metabolic disorder of the enzyme pyruvate kinase which affects the survival of red blood cells, Pyruvate Kinase Deficiency

RP-L301-0119 for Inherited metabolic disorder of the enzyme pyruvate kinase which affects the survival of red blood cells, Pyruvate Kinase Deficiency is a Phase 1 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

← All Lacuna Pharma Pty Ltd projects Phase 1 small molecule active

Internal code RP-L301-0119

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Lacuna Pharma Pty Ltd
Phase
Phase 1
Modality
small_molecule
Indication
Inherited metabolic disorder of the enzyme pyruvate kinase which affects the survival of red blood cells, Pyruvate Kinase Deficiency
Status
active
Trials
1